Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of MT-401-OTS, a scalable, off-the-shelf product candidate in acute Myeloid Leukemia patients

Next Previous
Trial Profile

A clinical trial of MT-401-OTS, a scalable, off-the-shelf product candidate in acute Myeloid Leukemia patients

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zedenoleucel (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Proof of concept

Most Recent Events

  • 25 Mar 2024 According to a Marker Therapeutics media release, the Company has received $2M funding from the NIH to support the clinical investigation of MT-401-OTS in patients with AML
  • 25 Mar 2024 According to a Marker Therapeutics media release, the Clinical program initiation of MT-401-OTS anticipated for the second half of 2024.
  • 07 Aug 2023 According to a Marker Therapeutics media release, the first patient will be treated with MT-401 OTS during the first half of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top